OCUMENSION THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.15 HKD | -4.03% |
|
+10.51% | +7.04% |
| 15/04 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| 15/04 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,433 | 9,507 | 5,967 | 4,193 | 4,595 | - | - |
| Enterprise Value (EV) 1 | 11,382 | 7,733 | 4,682 | 4,193 | 3,657 | 3,626 | 3,369 |
| P/E ratio | - | -33.2 x | -13.5 x | -10.3 x | -18.4 x | -88.3 x | 22.1 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1,026 x | 169 x | 37.5 x | 17 x | 10.4 x | 5.68 x | 3.16 x |
| EV / Revenue | 869 x | 138 x | 29.5 x | 17 x | 8.24 x | 4.48 x | 2.32 x |
| EV / EBITDA | -25.5 x | -20.1 x | -10.4 x | -10.7 x | -29.6 x | -81 x | 8.39 x |
| EV / FCF | - | -8.97 x | -14.8 x | - | 16.8 x | 38.2 x | 48.8 x |
| FCF Yield | - | -11.1% | -6.76% | - | 5.96% | 2.62% | 2.05% |
| Price to Book | 5.37 x | 2.79 x | 2.17 x | - | 1.72 x | 1.97 x | - |
| Nbr of stocks (in thousands) | 5,91,140 | 6,66,743 | 6,88,737 | 6,90,665 | 6,93,655 | - | - |
| Reference price 2 | 22.72 | 14.26 | 8.664 | 6.072 | 6.624 | 6.624 | 6.624 |
| Announcement Date | 19/03/21 | 25/03/22 | 30/03/23 | 21/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.1 | 56.15 | 159 | 246.4 | 443.6 | 809 | 1,455 |
| EBITDA 1 | -447.1 | -383.9 | -452.3 | -393.1 | -123.4 | -44.74 | 401.6 |
| EBIT 1 | -451.7 | -385.9 | -455.9 | -402.1 | -253.5 | -134 | 138 |
| Operating Margin | -3,449.28% | -687.36% | -286.78% | -163.23% | -57.15% | -16.57% | 9.48% |
| Earnings before Tax (EBT) 1 | - | -260 | -402.2 | -379.5 | -250.4 | -53.51 | 240.9 |
| Net income 1 | - | -260 | -402.6 | -379.8 | -250.9 | -3.016 | 204.8 |
| Net margin | - | -463.06% | -253.3% | -154.15% | -56.57% | -0.37% | 14.07% |
| EPS 2 | - | -0.4300 | -0.6400 | -0.5900 | -0.3600 | -0.0750 | 0.3000 |
| Free Cash Flow 1 | - | -861.7 | -316.5 | - | 218 | 95 | 69 |
| FCF margin | - | -1,534.67% | -199.09% | - | 49.14% | 11.74% | 4.74% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 17.18% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 33.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 19/03/21 | 25/03/22 | 30/03/23 | 21/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 11.14 | 20.8 | 35.34 | 54.54 | 104.4 | 103.7 | 142.7 | 169.5 | 259.7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | -179.7 | -206.2 | -218.5 | -237.4 | -224.9 | -177.3 | -152.3 | -132.8 |
| Operating Margin | - | - | -863.94% | -583.43% | -400.68% | -227.3% | -216.86% | -124.26% | -89.82% | -51.12% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | -1,742 | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | -27.00 | - | - | - | -0.3100 | -0.3300 | -0.3200 | -0.2700 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 26/08/20 | 19/03/21 | 20/08/21 | 25/03/22 | 26/08/22 | 30/03/23 | 24/08/23 | 21/03/24 | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 2,052 | 1,774 | 1,285 | - | 937 | 969 | 1,226 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -862 | -316 | - | 218 | 95 | 69 |
| ROE (net income / shareholders' equity) | -128% | -9.27% | -13.7% | - | -8.4% | -7.41% | - |
| ROA (Net income/ Total Assets) | - | -8.77% | -12.6% | - | -7% | -2.9% | - |
| Assets 1 | - | 2,965 | 3,187 | - | 3,585 | 104 | - |
| Book Value Per Share 2 | 4.230 | 5.120 | 3.990 | - | 3.860 | 3.370 | - |
| Cash Flow per Share 2 | - | -0.3200 | -0.3200 | - | 0.4200 | 0.3000 | - |
| Capex 1 | - | 665 | 116 | - | 75 | 114 | 167 |
| Capex / Sales | - | 1,184.07% | 72.86% | - | 16.91% | 14.09% | 11.48% |
| Announcement Date | 19/03/21 | 25/03/22 | 30/03/23 | 21/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.624
CNY
Average target price
7.77
CNY
Spread / Average Target
+17.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.04% | 635M | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- 1477 Stock
- Financials Ocumension Therapeutics
